Schulte Johannes H, Schramm Alexander, Klein-Hitpass Ludger, Klenk Michael, Wessels Hendrika, Hauffa Berthold P, Eils Jürgen, Eils Roland, Brodeur Garrett M, Schweigerer Lothar, Havers Werner, Eggert Angelika
University Children's Hospital of Essen, Germany.
Oncogene. 2005 Jan 6;24(1):165-77. doi: 10.1038/sj.onc.1208000.
Expression of neurotrophin receptors of the tyrosine kinase receptor (Trk) family is an important prognostic factor in solid tumors including neuroblastoma. High expression of TrkA (NTRK1) is associated with a favorable biology and outcome of neuroblastoma, whereas TrkB (NTRK2) is expressed on aggressive neuroblastomas with unfavorable outcome. To gain new insights into the global gene expression program resulting in these divergent biological phenotypes, we stably expressed either TrkA or TrkB in the human SH-SY5Y neuroblastoma cell line. Gene expression profiles were obtained from parental cells and transfectants activated by their ligands in a time course over 24 h using oligonucleotide microarrays. Basal activation of Trk receptors in the absence of exogenous ligand was sufficient to induce broad and divergent genetic changes. Global gene regulation following external ligand stimulation was surprisingly similar in SY5Y-TrkA and SY5Y-TrkB cells except for the differential expression of distinct novel target genes. Consistent with their divergent biological phenotype, SY5Y-TrkA cells were characterized by upregulation of proapoptotic genes and angiogenesis inhibitors, whereas SY5Y-TrkB cells demonstrated upregulation of genes involved in invasion or therapy resistance. We suggest that the transcriptional program of neuroblastoma cells is modulated by Trk-receptor expression and basal activation rather than by ligand-induced activation. Fine-tuning of the malignant phenotype may be achieved by additional ligand stimulation with subsequent activation of a few specific genes.
酪氨酸激酶受体(Trk)家族神经营养因子受体的表达是包括神经母细胞瘤在内的实体瘤的重要预后因素。TrkA(NTRK1)的高表达与神经母细胞瘤良好的生物学特性和预后相关,而TrkB(NTRK2)则表达于预后不良的侵袭性神经母细胞瘤。为了深入了解导致这些不同生物学表型的整体基因表达程序,我们在人SH-SY5Y神经母细胞瘤细胞系中稳定表达了TrkA或TrkB。使用寡核苷酸微阵列,在24小时的时间进程中,从亲代细胞和被其配体激活的转染子中获得基因表达谱。在没有外源性配体的情况下,Trk受体的基础激活足以诱导广泛而不同的基因变化。除了不同新靶基因的差异表达外,SY5Y-TrkA和SY5Y-TrkB细胞在外部配体刺激后的整体基因调控惊人地相似。与它们不同的生物学表型一致,SY5Y-TrkA细胞的特征是促凋亡基因和血管生成抑制剂上调,而SY5Y-TrkB细胞则表现出参与侵袭或治疗抗性的基因上调。我们认为,神经母细胞瘤细胞的转录程序是由Trk受体表达和基础激活调节的,而不是由配体诱导的激活调节的。通过额外的配体刺激以及随后激活一些特定基因,可能实现恶性表型的微调。